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http://dx.doi.org/10the prostate is commonly performed using transrec-
tal ultrasound (US) guidance, with CT imaging used for needle reconstruction and treatment
planning. Transrectal ultrasound images can, however, be used for the entire process, allowing
treatment without changes in the patient position. This study assesses needle reconstruction
accuracy using US images.
METHODS AND MATERIALS: Prostate phantoms were implanted with 10e18 needles. Three-
dimensional US images were acquired, and needles were reconstructed using specialized software.
A CT scan was also obtained. The image sets were registered and needle reconstruction errors were
assessed. A dose plan was obtained using the US images and the dwell times were transferred to the
CT reconstruction to obtain the true ‘‘delivered dose,’’ which was evaluated using standard dosi-
metric parameters.
RESULTS: Two sources of error were identified. First, reconstruction based on the bright echoes in
the US images introduces a systematic error because these echoes correspond to the proximal wall of
the needle, and not the center of the needle channel. If left uncorrected, this shift can lead to an under-
estimate of urethral doses. Second, incorrect needle tip identification can occur in the craniale
caudal direction. Errors up to 5.8 mm were observed. A measurement of needle lengths protruding
beyond the template can be used to compensate for this.
CONCLUSIONS: Factors limiting the accuracy of US-based needle reconstruction have been
identified. Once recognized, these errors can be corrected for, resulting in accurate implant geom-
etry. This facilitates a treatment technique combining excellent anatomic definition, minimal
prostate motion, and accurate dose planning and delivery.  2013 American Brachytherapy Society.
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.1016/j.brachy.2012.03.002the prostate through which an HDR radioactive source can
be introduced using an afterloading device. Before delivery
of the treatment, needle placement with respect to the
prostate and organs at risk (OARs) must be determined
and, based on this, a suitable dose plan must be generated.
Typically, prostate HDR-BT begins with the insertion of
needles into the prostate under transrectal ultrasound
(TRUS) guidance with the patient in the dorsal lithotomy
position. There are advantages to using TRUS for this, most
notably that the prostate and urethra are well visualized in
ultrasound (US) images making development of appro-
priate implant geometry relatively straightforward.
Additionally, needle placement can be followed in real time
during insertion, which allows for adjustment of subsequenthed by Elsevier Inc. All rights reserved.
57M. Schmid et al. / Brachytherapy 12 (2013) 56e64needle positions to compensate for any nonideal needle
placement.
Following needle implantation, the most common practice
is to send the patient for a CT scan. Typically, this requires
lowering the patient’s legs and transferring the patient onto
and off of both a stretcher and aCT scanner table. After acqui-
sition of the CT images, the target andOARare contoured, the
implant geometry is reconstructed, and a dose plan based on
theCTimages is produced.When the reconstruction and plan-
ning are complete, the treatment may be delivered.
CT is known to be geometrically accurate and is an
excellent imaging modality for identifying the needle
locations. However, the change in position of the patient’s
legs, the movement of the patient, and the delay between
imaging and treatment are all known to produce changes
to the needle positions and/or implant geometry (1e8).
This is problematic because any such changes will result
in differences between the planned dose and the dose that
is actually delivered to the prostate and to the adjacent
organs. When multiple fractions are delivered based on
a single plan, which is often the case with CT-based
planning but is not done with the one-step US-based proce-
dure investigated here, the problem of needle migration is
of even greater concern.
An alternate approach to prostate HDR-BT is to use
TRUS imaging both to guide the implantation of needles
and for treatment planning. In this process, implantation
of the needles, three-dimensional (3D) imaging, dose
planning, and treatment are integrated into a single
process that does not require any change in patient posi-
tion or movement of the patient. This approach solves
many problems related to patient and needle motion, but
does present other challenges. Although the prostate is
generally much better delineated on TRUS compared with
CT, TRUS images are not as geometrically accurate, and
ultrasonic shadows produced by posterior needles often
obscure the exact needle placement of more anterior nee-
dles. To realize the potential gains of this approach, the
effects of these limitations on needle reconstruction must
be understood. Highly accurate treatment plans can only
be achieved through accurate reconstruction of the implant
geometry.Fig. 1. (a) Midprostate transverse view of the phantom obtained usinThe purpose of this study is to evaluate the accuracy of
the implant reconstructions based on TRUS images using
Vitesse software (Varian Medical Systems, Palo Alto, CA).Methods and materials
Specialized prostate US phantoms (model 053MM;
Computerized Imaging Reference Systems Inc., Norfolk,
VA) were used for this study. These phantoms incorporate
internal structures (prostate, urethra, seminal vesicles, and
two nodules) that are clearly visible in both US and CT
images. A transverse TRUS image of one of the phantoms
and its corresponding CT image are shown in Figs. 1a and
1b, respectively. The central structure is the urethra. The
structure on the left side of the images is a simulated
nodule. These nodules proved useful in registering the
images, but are otherwise not relevant to this study.
Six phantoms were implanted under US guidance using
a standard technique for TRUS-based implants. The number
of needles implanted in each phantomvaried from10 to 18. In
each phantom, the prostate was visualized on TRUS (Flex
Focus; B&KMedical Systems, Peabody, MA) at a midgland
position, and the needles were implanted using a standard
implant template. The needles were first advanced to the
midgland position under TRUS guidance in the transverse
mode. After all needles had been advanced to this position,
the longitudinal transducerwas selected and the needleswere
advanced one at a time to the base of the prostate. The posi-
tions of the needle tips in the cranialecaudal direction were
tracked in the live image during this process, and their final
positions were determined during this step. This last step is
always carried out from anterior to posterior so that the nee-
dles do not fall into the shadow of more posterior needles as
they are advanced. The needles used in this study (Varian
Medical Systems) were plastic with a diameter of 2 mm.
After the completion of the implant, 3D US images of
the phantoms were acquired using the Vitesse (Varian) soft-
ware program. This software makes two modes available
for 3D reconstruction. In Twister (Varian Medical Systems)
mode, the probe is rotated about its long axis as images are
acquired using the longitudinal transducer. The rotationalg ultrasound and (b) the corresponding view obtained using CT.
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rated into the TRUS probe holder (CIVCO EXII; Civco
Medical Solutions, Kalona, IA). A 3D image is then
reconstructed from the multiple longitudinal images. A
more conventional transverse mode is also available, in
which the probe is translated in the cranial/caudal direction
as images are acquired using the transverse transducer. In
this case, the linear position of the probe is determined
by a second encoder on the probe holder. Although image
sets were acquired using both of these modes, this work
focuses on the results obtained using the conventional
linear acquisition.
The 3D images acquired suffer from a number of limita-
tions inherent in US imaging, namely poor delineation of
the needles, spatial inaccuracies, and shadowing. To deal
with these limitations, special tools incorporated into the
Vitesse (Varian) software program are used to reconstruct
the needle paths. This is of special relevance because theseFig. 2. A view of the Vitesse (Varian) screen showing the path imagtools define exactly how the individual needles are placed
with respect to the images.
The Vitesse (Varian) software is designed to facilitate
tracking the bright flashes in the TRUS image. This tool
works well even when tracking curved needles. When a nee-
dle has been tracked properly, the display will show
a straight line in the needle path images, labeled ‘‘Path
Image 1’’ and ‘‘Path Image 2’’ as shown in the two bottom
right panes of Fig. 2. The software then places the center of
the needle along the identified path, which corresponds to
the bright flash in the image. This technique was used to
define the needle paths in the US images for all phantoms.
After the US imaging was complete, the phantoms were
taken to a CT scanner and imaged with high resolution
(slice thickness: 0.625 mm). The spatial accuracy and the
clearly visible needle channels make accurate needle recon-
struction possible. In this study, the CT image set is taken
as the gold standard, that is, differences in geometryes used to track the needle positions in the lower right panel.
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inaccuracies in the US data.
The US image set, along with the reconstructed needle
paths, were then transferred to a dose calculation program
(BrachyVision; Varian Medical Systems).
The prostate, urethra, and a surrogate for the rectum
were contoured in the US image set and an optimized dose
distribution was produced. Active dwell positions were
defined in each needle within a margin around the prostate.
The margins used were 7 mm superior, 5 mm inferior,
lateral and anterior, and 0 mm posterior. The objectives
were to cover the prostate with a dose of 1000 cGy, while
limiting the dose to the urethra and the rectum. The urethral
constraint was a maximum dose of 1150 cGy. The rectal
constraint was that no more than 1 cc should receive a dose
higher than 750 cGy.
The CT data set was also imported into BrachyVision
and the TRUS image set was then registered to the CT data
set based on the anatomic structures in the phantoms. The
prostate volume was contoured in the CT data set to aid
in this registration and to assess the consistency of the con-
touring. The comparison between the CT and US prostate
volumes is shown in Table 1. The differences between the
reconstructed dwell locations in the US data set and the cor-
responding positions in the CT data set were tabulated. The
dwell locations (and corresponding dwell times) in the US
plan were then moved to their correct locations as deter-
mined in the CT images to produce a representation of
the true delivered dose. The results were evaluated using
a number of dosimetric parameters, including D90 (theTable 1
The effect of needle reconstruction accuracy on the dose delivered to the prosta
Phantom
number 1 2 3 4
Number
of needles 16 14 10 18
US CT US CT US CT US
Prostate
volume
62.4 61.8 59.6 62.2 61.4 60.3 62.2
V100% 92.9 89.4 95.8 94.2 93.5 90.0 96.1
D100% 62.0 62.0 74.3 70.6 67.1 58.3 74.6
D90% 104.3 99.4 106.4 104.4 105.1 100.1 108.8
V150% 26.7 22.9 26.6 22.3 26.4 23.2 29.8
V125% 55.2 47.8 55.1 51.0 52.6 46.9 60.5
V200% 7.1 6.1 8.4 6.0 9.6 8.4 8.1
Rectum max 80.2 70.1 75.3 71.7 78.9 70.8 80.0
Rectum D1cc 66.4 60.1 68.0 64.4 69.4 64.3 69.5
Rectum V70% 3.1 0.0 3.7 0.3 5.6 0.1 5.8
Urethra max 112.8 116.9 112.9 116.7 114.9 113.3 116.5
Urethra D1cc 106.5 103.0 106.9 106.1 109.1 107.0 110.7
Urethra V115% 0.0 0.1 0.0 0.1 0.0 0.0 0.3
US5 ultrasound; V100, (V125, V150, V200)5% of the prostate volume receiv
(D100)5 isodose as a % of the prescription dose, enclosing 90% (100%) of th
as a % of the prescription dose; rectum D1cc5Dose to 1 cc of the rectal wall as
centimeter receiving a minimum of 70% of prescription dose; urethra max5max
D1cc5Dose to 1 cc of the urethra as % of prescription dose; urethra V115%5 v
prescription dose.minimum dose received by 90% of the prostate volume),
V100 and V150 (percentage of the prostate volume enclosed
by the 100% and 150% isodose), and the doses to the
urethra and rectal surrogate.Results
Images from the CT data set for one of the implants are
shown in Fig. 3. Note that the solid plastic tips of the nee-
dles are clearly visible and that the air channel inside each
needle is very well defined. Reconstruction of the air spaces
is what determines the location of the source dwell posi-
tions, and it is apparent that the needle reconstruction can
be carried out accurately using these images. By way of
contrast, Fig. 4 shows the same views in the US image.
Although some of the needles are well visualized in the
US image, others are not. In this extreme case (which
was the worst in the study), the needle highlighted in the
transverse view is almost completely obscured in the US
image. Although needle shadowing occurs frequently to
some extent, the tools incorporated in the Vitesse (Varian)
software, and in particular the path images tool, allow accu-
rate needle tracking even in cases where a large part of the
track is obscured. This image is taken from a phantom,
which was implanted with 16 needles. In general, this
problem of ‘‘needle shadowing’’ becomes markedly worse
as the number of needles in the implant increases.
Figure 5 shows the result of registering the US image to
the CT image. It is immediately apparent that the brightte and organs at risk as evaluated by standard dosimetric parameters
5 6
Average Average
difference
12 16
CT US CT US CT US CT
63.1 64.1 64.1 63.1 62.2 62.1 62.3 0.2
94.2 92.9 91.6 95.8 93.1 94.5 92.1 2.4
74.0 66.9 66.7 72.1 72.7 69.5 67.4 2.1
106.4 105.0 102.5 105.6 102.7 105.9 102.6 3.3
27.8 30.2 28.8 25.3 24.0 27.5 24.8 2.7
57.1 57.1 53.3 55.9 51.8 56.1 51.3 4.8
7.4 11.1 10.3 7.6 6.6 8.7 7.5 1.2
74.6 80.5 75.5 77.1 74.4 78.7 72.9 5.8
64.7 67.8 63.1 68.1 64.2 68.2 63.5 4.7
1.1 3.7 0.8 4.1 1.0 4.3 0.6 3.7
121.7 122.3 132.3 115.8 117.0 115.9 119.7 3.8
109.7 110.7 109.2 108.4 107.8 108.7 107.1 1.6
0.3 0.3 1.0 0.2 0.9 0.1 0.4 0.3
ing 100%, (125%, 150%, 200%) of the prescription dose or greater; D90
e prostate volume; rectum max5maximum dose received by the rectum
% of prescription dose; rectum V70%5 volume of the rectal wall in cubic
imum dose received by the urethra as a % of the prescription dose; urethra
olume of the urethra in cubic centimeter receiving a minimum of 70% of
Fig. 3. Orthogonal views of an implanted phantom obtained using CT. The air spaces in the needles are very well defined. All needles are clearly visible.
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the needles, but rather to the wall of the needle proximal to
the US transducer. Because the Vitesse (Varian) software is
designed to track the bright flashes, there will be an obvious
systematic error in the reconstruction of the implant. If the
relationship between the US flash and the needle location as
described above is understood, the needle locations can be
adjusted accurately in the transverse views.
The exact location of each needle tip in the cranialecaudal
direction must also be determined if the needle position is to
be accurately reconstructed. For needles that are well visual-
ized in the US image, this is not a problem. For needles that
are obscured, however, it can be very difficult.Figure 6 shows the distribution of the displacements
(millimeter) of the first dwell positions in the US images
from their correct positions as determined from the CT
images for all the needles in all six phantoms. These
displacements were calculated in a cylindrical coordinate
system. The radial component is measured radially
outward from the probe, the angular component represents
a rotation in the transverse plane, and the third component
is in the cranial/caudal direction. The systematic error
caused by defining the needle paths along the flash in the
US images is again readily apparent. This is evidenced
by the fact that the displacement distribution for the radial
direction is not centered about zero. Naively, one would
Fig. 4. The ultrasound view showing the same orthogonal planes shown in Fig. 3. The highlighted needle is completely obscured by some of the posterior
needles.
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radius of the needles (in our case 1.0 mm). In fact, the
average error in this direction was 1.0 mm. The errors in
the angular component are distributed relatively evenly
about zero, as are the errors in the cranialecaudal
direction.
These measured displacements are based solely on the
Vitesse (Varian) reconstructions of the needle paths. For
cases where a needle falls in the shadow of a lower needle,
the path reconstruction can be very unreliable. Because the
needles all curve to some extent, it is unlikely that one
needle will be obscured along its entire length. This usually
allows for a reasonably accurate reconstruction of its radial
and angular position, at least at a number of points along itslength. If however, the needle is obscured at its tip, there is
no other information available in the image that can be used
to position its tip properly in the cranialecaudal direction.
This can result in relatively large errors in this direction,
which accounts for the outliers in the histogram.
Ultimately, the importance of needle reconstruction
accuracy lies in the effect on the dose delivered to the target
and the OARs. A number of dosimetric parameters were
used to evaluate this and these are summarized in Table 1.
The target doses in the US-based plan generally show
only small differences relative to those determined based
on the CT needle reconstruction. The doses to the OARs,
however, showed some larger changes. These can be attrib-
uted almost entirely to the systematic error in the radial
Fig. 5. A transverse view of the registered CT and ultrasound (US)
images. Note that the centers of the needles lie above the bright flashes
in the US image.
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line corresponding to the maximum allowed urethral dose
generally conforms very closely to the urethral structure.
These dose distributions were, however, determined based
on incorrect needle positions. When the distributions are
transferred to the CT-determined needle positions, which
represent the dose that would be delivered, the distributions
are shifted, moving the high-dose region into the urethra.
This is illustrated in Fig. 7, where Fig. 7a shows the dose
planned on the basis of the US images, and Fig. 7b shows
the dose that would be delivered based on the CT images.
The largest change in the urethral maximum dose was an
increase of 10%, with the average change being 3.8% of
the prescribed dose.Fig. 6. Histograms of the measured displacements between the ultrasound-
reconstructed needle tip positions and the CT-reconstructed positions in the
radial, angular, and cranialecaudal directions. Note that the distribution of
the radial displacements is not centered on zero.The changes in the doses to the rectum are negative in
all cases, meaning the rectal dose is lower than the dose
predicted by the US reconstruction. In this case, correcting
for the systematic error in the radial direction moves the
dose cloud away from the rectum.Discussion
Until the recent introduction of TRUS-based planning
for prostate HDR-BT, the major drawback of this modality
has been the need for a multistep procedure involving:
1. TRUS-guided needle insertion under anesthesia in the
dorsal lithotomy position
2. Transportation of the patient to a CT scanner for CT
imaging in the supine position and CT-based planning
3. Transportation of the patient back to the treatment
delivery suite
4. Reverification of needle position and adjustment of
the cranialecaudal depth of insertion
The multistep nature of CT-planned prostate HDR-BT
prolongs the process; limits the number of cases that can
be done in a day; adds discomfort and inconvenience for
the patient; and, most importantly, introduces an unaccept-
able source of error owing to needle retraction in the caudal
direction away from the base of the prostate. Mean
displacements have been reported of 3e11 mm with a range
up to 28 mm (1e3,6e8). It is felt that any displacement
greater than 3 mm should be corrected (3). Inaccuracies
are inherent in the readjustment of the depth of insertion
several hours postimplantation with the patient awake
(1,3e6). TRUS-based planning allows both the procedure
and treatment to be performed in a single location and
under anesthesia, eliminating both the risk of needle
displacement during patient transfer, and associated patient
discomfort while being transferred and repositioned with
the needles in place. However, to rely on TRUS-based
planning, one must be confident that the TRUS-identified
needle positions represent the actual 3D coordinates of that
needle relative to the prostate and adjacent normal
structures.
Implant reconstruction involves identification of the nee-
dle tips and the needle path accurately. ‘‘Tip location’’ posi-
tions the needle in the cranialecaudal direction and thus
determines the location of the source dwell positions
relative to the anatomy in the treatment plan. Others have
studied the accuracy of needle tip identification (9) and
have found the locations of needle tips in general to be
accurate; however, their study was idealized in that they
were identifying individual needle tips inserted one at a time
into a water bath. In practice, the challenge is to identify
needle locations in a geometric arrangement of multiple
needles. Needle tip location in this phantom study was
determined to have median difference of 0.5 mm (range,
5.8e3.4 mm) compared with the CT-based tip location.
Fig. 7. (a) The optimized dose distribution based on the ultrasound reconstruction. The yellow line represents the 115% isodose line. (b) The corrected dose
distribution based on the CT reconstruction. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this
article.)
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differences were less than 2.0 mm (Fig. 6); however, the
magnitude of the outlying discrepancies is clearly unac-
ceptable. Although misidentifying the tip of a small number
of needles per implant did not have as large a negative
impact on overall dosimetry as the systematic shift in nee-
dle channel positions did, this error will result in local dosi-
metric changes that may be important if the planned dose
cloud surrounding the needle is actually closer to OAR
structures or farther from target structures.
There are a number of strategies that can be used to miti-
gate this problem. As difficulty in identifying needle tip
location is increased when the needle under consideration
falls in the shadow of a more posterior needle, one possi-
bility is to track and identify the tips of the more anterior
needles first. This can be accomplished by observing theTable 2
Comparison of standard dosimetric parameters from CT-based reconstruction and
in radial direction
Phantom
number 1 2 3 4
Number
of needles 16 14 10 18
US CT US CT US CT US
Prostate
volume
62.4 61.8 59.6 62.2 61.4 60.3 62.2
V100% 92.0 89.4 94.0 94.2 91.8 90.0 94.1
D100% 62.5 62.0 74.7 70.6 65.3 58.3 76.2
D90% 102.6 99.4 104.2 104.4 102.8 100.1 106.1
V150% 23.9 22.9 23.1 22.3 24.1 23.2 26.9
V125% 51.2 47.8 50.6 51.0 48.1 46.9 55.4
V200% 6.1 6.1 6.3 6.0 9.2 8.4 7.3
Rectum max 71.7 70.1 69.7 71.7 71.5 70.8 72.7
Rectum D1cc 61.7 60.1 63.0 64.4 64.3 64.3 64.2
Rectum V70% 0.2 0.0 0.0 0.3 0.1 0.1 0.7
Urethra max 113.3 116.9 113.1 116.7 112.4 113.3 118.6
Urethra D1cc 104.9 103.0 105.5 106.1 106.7 107.0 108.4
Urethra V115% 0.1 0.1 0.0 0.1 0.0 0.0 0.2
US5 ultrasound;V100, (V125, V150,V200)5%of the prostate volume receiving
isodose as a%of the prescriptiondose, enclosing90% (100%)of the prostatevolume
tion dose; rectum D1cc5Dose to 1 cc of the rectal wall as % of prescription dos
a minimum of 70% of prescription dose; urethra max5maximum dose received
of the urethra as % of prescription dose; urethra V115%5 volume of the urethra intips using longitudinal US images as the needle is advanced
to its final position. The Vitesse (Varian) software has tools
that aid in doing this and allow one to lock down the tip
position of each needle as it is identified. Care must be
exercised, however, to ensure that the needles do not move
once the tip has been identified.
Measuring the lengths of the needles that protrude from
the implant template can provide a check that the needles
have not moved and ameliorate difficult needle tip identifi-
cations. Knowing this length, it would be possible, using
knowledge of the physical location of the TRUS transducer
with respect to some external mark on the probe, to deter-
mine exactly where the needle tip was with respect to the
plane of the TRUS transducer. In practice, however, it is
more practical to use the measured lengths of the
protruding needles to determine the tip locations relativeUS-based reconstruction after application of systematic correction of 1 mm
5 6
Average Average
difference
12 16
CT US CT US CT US CT
63.1 64.1 64.1 63.1 62.2 62.1 62.3 0.2
94.2 91.3 91.6 93.3 93.2 92.8 92.1 0.7
74.0 66.8 66.7 71.0 72.7 69.4 67.4 2.0
106.4 101.9 102.5 103.4 103.9 103.5 102.8 0.7
27.8 28.0 28.8 22.8 24.2 24.8 24.9 0.1
57.1 52.6 53.3 51.1 52.6 51.5 51.5 0.0
7.4 10.1 10.3 5.1 6.5 7.4 7.5 0.1
74.6 73.3 75.5 70.7 73.9 71.6 72.8 1.2
64.7 62.8 63.1 63.0 63.5 63.2 63.4 0.2
1.1 0.7 0.8 0.0 0.5 0.3 0.5 0.2
121.7 132.0 132.3 116.7 118.5 117.7 119.9 2.2
109.7 108.1 109.2 107.2 108.3 106.8 107.2 0.4
0.3 0.7 1.0 0.4 1.2 0.2 0.5 0.3
100%, (125%, 150%, 200%) of the prescription dose or greater;D90 (D100)5
; rectummax5maximumdose received by the rectumas a%of the prescrip-
e; rectum V70%5 volume of the rectal wall in cubic centimeter receiving
by the urethra as a % of the prescription dose; urethra D1cc5Dose to 1 cc
cubic centimeter receiving a minimum of 70% of prescription dose.
64 M. Schmid et al. / Brachytherapy 12 (2013) 56e64to one of the lower needles that are well visualized in the
image. This technique was applied to the needles in the
phantom study, and this reduced the maximum error in
the cranialecaudal direction from 5.8 to 1.9 mm. Using
both strategies in combination to improve needle tip identi-
fication provides a robust needle tip identification and
quality assurance process.
Regarding needle path reconstruction, the registration of
the TRUS images with CT has revealed that the dominant
discrepancy when using the Vitesse (Varian) software is
a systematic error in determining the radial position of the
needle. This results in the needle channel being recon-
structed 1.0 mm closer to the probe than its actual location
as determined by CT imaging. Because this was a consistent
phenomenon, prior knowledge of this discrepancy between
TRUS- and CT-based needle reconstruction allows one to
make a straightforward systematic correction to compensate
for it. Table 2 shows the changes in dosimetric parameters
between the US-based reconstruction with a systematic
correction of 1.0 mm applied in the radial direction and the
CT-based reconstruction. Making the correction in the radial
direction significantly reduces the discrepancies between the
two data sets. After correction, the largest residual error was
in the maximum urethral dose, which is the parameter most
sensitive to needle positioning. The greatest increase in the
maximum urethral dosewas reduced to 3.7% and the average
difference was reduced to 2.2% (of prescription dose). The
differences in the rectal doses between the corrected US data
and the CT data were very small.Conclusions
One-step TRUS-based planning represents a significant
advance in the delivery of prostate HDR-BT, making the
procedure more efficient in resource utilization as well as
more convenient and comfortable for the patient. This
approach also increases dose delivery accuracy as the lack
of patient repositioning between implantation and treatment
delivery removes the threat of needle migration. The
improved accuracy of dose delivery of a one-step TRUS-
based procedure brings the ultimate goal of dose escalation
to dominant intraprostatic nodules closer to reality (10e12).
Achievement of these advantages does, however, depend
on accurate reconstruction of the implant geometry. This
study demonstrates two potential sources of error in needle
path reconstruction: uncertainty in the identification ofneedle tips owing to US artifacts and a systematic shift in
the reconstructed position of the needle channels owing
to the way in which the Vitesse (Varian) software is used
to track needle paths. Knowledge of these errors has,
however, allowed us to develop strategies to minimize, in
the case of needle tip misidentification, or eliminate, in
the case of the systematic shift in needle positions, their
impact on overall implant quality.References
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